Anzeige
Erschienen in:
14.04.2015 | original article
Can circulating M30 and M65 levels be beneficial markers in the diagnosis and management of patients with complete hydatidiform mole?
Erschienen in: Wiener klinische Wochenschrift | Sonderheft 8/2016
Einloggen, um Zugang zu erhaltenAbstract
Objective
The objective of this study is to evaluate the prognostic value of M30 and M65 levels as markers of apoptotic activity and maternal serum oxidative stress in patients with complete hydatidiform mole (CHM).
Methods
In total, 68 pregnant women were included in the study. The study group included 34 pregnant with CHM, while 34 healthy pregnant were employed as a control group. Venous blood samples were drawn to assess the maternal serum oxidative stress and M30–M65 levels. In addition, a second blood sample was drawn from patients with CHM on day 8 after dilatation evacuation.
Results
Maternal serum oxidative stress and M30–M65 levels were found to be significantly higher in patients with CHM as compared with the control group. It was found that serum β-subunit of human chorionic gonadotropin (β-hCG) level had a significant positive correlation with M30–M65 levels in patients with CHM. In addition, serum M65 level was found to be as effective as β-hCG in the identification of the patients with CHM.
Conclusion
Our results indicated that oxidative stress and apoptosis may play significant roles in CHM development. In addition, it seems that serum M30–M65 levels can presumably be an ancillary laboratory test to β-hCG in the diagnosis and follow-up of the patients with CHM.